Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 25, 2024

Dapagliflozin for the Treatment of Patients With Critical Illness and Acute Organ Dysfunction

JAMA: The Journal of the American Medical Association


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial
JAMA 2024 Jun 14;[EPub Ahead of Print], CAM Tavares, LCP Azevedo, Á Rea-Neto, NS Campos, CP Amendola, AC Kozesinski-Nakatani, PG David-João, SM Lobo, TC Filiponi, GMB Almeida, RR Bergo, MRR Guimarães-Júnior, RC Figueiredo, JR Castro, CJ Schuler, GA Westphal, ACR Carioca, F Monfradini, J Nieri, FMO Neves, JA Paulo, CSN Albuquerque, MCR Silva, MN Kosiborod, AJ Pereira, LP Damiani, TD Corrêa, A Serpa-Neto, O Berwanger, FG Zampieri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading